2025
TET3 is a common epigenetic immunomodulator of pathogenic macrophages
Liu B, Dai Y, Wang Z, Song J, Du Y, Lv H, Bellone S, Yang Y, Kennedy A, Zhang S, Venkatachalapathy M, Surovtseva Y, Wang P, Carmichael G, Taylor H, Zhang X, Li D, Huang Y. TET3 is a common epigenetic immunomodulator of pathogenic macrophages. Journal Of Clinical Investigation 2025 PMID: 40794443, DOI: 10.1172/jci194879.Peer-Reviewed Original ResearchThis study investigates the role of TET3 in promoting pathogenic macrophages across chronic inflammatory diseases, and shows that selectively eliminating TET3-overexpressing macrophages (“Toe-Macs”) can mitigate disease progression in conditions like MASH, NSCLC, and endometriosis.
2024
TET3-overexpressing macrophages promote endometriosis
Lv H, Liu B, Dai Y, Li F, Bellone S, Zhou Y, Mamillapalli R, Zhao D, Venkatachalapathy M, Hu Y, Carmichael G, Li D, Taylor H, Huang Y. TET3-overexpressing macrophages promote endometriosis. Journal Of Clinical Investigation 2024, 134: e181839. PMID: 39141428, PMCID: PMC11527447, DOI: 10.1172/jci181839.Peer-Reviewed Original ResearchDisease-associated macrophagesTET3 overexpressionHuman endometriosis lesionsPathophysiology of endometriosisPro-inflammatory cytokine productionChronic inflammatory diseaseReproductive age womenEndometriosis lesionsE3 ubiquitin ligasePathogenic macrophagesCytokine productionEndometriosisInflammatory diseasesTET3 knockdownEndometriosis progressionPathogenic contributorsLet-7 miRNA expressionAge womenMacrophagesMouse macrophagesTherapeutic targetUbiquitin ligaseTET3MiceDisease
2019
Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain
Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Management 2019, 9: 497-515. PMID: 31434540, DOI: 10.2217/pmt-2019-0010.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painPain symptomsEstrogen-dependent chronic inflammatory diseaseSevere endometriosis-associated painCurrent medical treatment optionsNonmenstrual pelvic painPelvic pain symptomsMedical treatment optionsChronic inflammatory diseasePathophysiology of endometriosisRole of estrogenEstrogen suppressionCentral sensitizationPelvic painTreatment optionsClinical evaluationInflammatory diseasesPainClinical developmentHigh dosesLow dosesElagolixUS FDAEndometriosisSymptoms
2018
microRNA Let‐7b: A Novel treatment for endometriosis
Sahin C, Mamillapalli R, Yi KW, Taylor HS. microRNA Let‐7b: A Novel treatment for endometriosis. Journal Of Cellular And Molecular Medicine 2018, 22: 5346-5353. PMID: 30063121, PMCID: PMC6201226, DOI: 10.1111/jcmm.13807.Peer-Reviewed Original ResearchConceptsLet-7bSide effectsSystemic hormonal side effectsMicroRNA let‑7bReproductive-aged womenHormonal side effectsTreatment of endometriosisCurrent treatment optionsChronic inflammatory diseaseSteroid hormone modulationGrowth factor receptorIL-6Treatment optionsEndometriosis growthEndometriosis pathophysiologyInflammatory diseasesChronic diseasesLocal treatmentPromising therapyMurine modelEndometriosisHormone modulationNovel treatmentsLesion sizeMicroRNAs treatmentsG-Protein-Coupled Receptor CXCR7 Is Overexpressed in Human and Murine Endometriosis
Pluchino N, Mamillapalli R, Moridi I, Tal R, Taylor HS. G-Protein-Coupled Receptor CXCR7 Is Overexpressed in Human and Murine Endometriosis. Reproductive Sciences 2018, 25: 1168-1174. PMID: 29587613, PMCID: PMC6346303, DOI: 10.1177/1933719118766256.Peer-Reviewed Original ResearchConceptsG protein-coupled receptorsNormal endometrial epitheliumChronic inflammatory diseaseOverexpression of CXCR7Chemokine ligand CXCL12Chemokine G-protein-coupled receptorsMurine endometriosisDifferent cellular populationsHuman endometriosisInflammatory diseasesMenstrual cycleChemokine receptorsReceptor CXCR7Endometrial epitheliumEndometriosis pathogenesisLigand CXCL12Murine modelMouse modelEndometriosisHigher stainingCXCR7Human findingsCell traffickingLow expressionNovel target
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply